This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
69
multiple doses of CFZ533 s.c. injection
multiple doses of placebo s.c. injection
multiple doses of CFZ533 intravenous infusion
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Mineola, New York, United States
Novartis Investigative Site
Duncansville, Pennsylvania, United States
Novartis Investigative Site
Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)
The effect of CFZ533 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.
Time frame: Baseline and Week 12
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI)
The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms.
Time frame: Baseline and Week 12
Change From Baseline in Physician Global Assessment of the Patient's Overall Disease Activity (VAS)
The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).
Time frame: Baseline and Week 12
Change From Baseline in Patient's Global Assessment of Their Disease Activity (VAS)
The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).
Time frame: Baseline and Week 12
Change From Baseline in Short Form (36) Health Survey (SF-36) Physical Component Score
The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
multiple doses of placebo intravenous infusion
multiple doses of CFZ533 s.c. injection
Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
Berlin, Germany
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Basel, Switzerland
Novartis Investigative Site
Edgbaston, Birmingham, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Newcastle upon Tyne, United Kingdom
Time frame: Baseline and Week 12
Change From Baseline in Short Form (36) Health Survey (SF-36) Mental Component Score
The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.
Time frame: Baseline and Week 12
Change From Baseline in Multidimensional Fatigue Inventory (MFI)
The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a possible range from 4-20. The reported total score has a range from 20-100. A reduction from baseline in MFI indicates improvement.
Time frame: Baseline and Week 12